Sangamo Therapeutics

company

About

Sangamo researches, develops and commercializes engineered DNA-binding proteins for the development of novel therapeutic strategies.

  • 251 - 500

Details

Last Funding Type
Grant
Last Funding Money Raised
$11M
Industries
Biotechnology,Genetics,Health Care,Pharmaceutical,Therapeutics
Founded date
Jan 1, 1995
Number Of Employee
251 - 500
Operating Status
Active

Sangamo Therapeutics is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The company's product pipeline includes Hemophilia, Central Nervous System, HIV, Lysosomal Storage Disorders, and Hemoglobinopathies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$11M
Sangamo Therapeutics has raised a total of $11M in funding over 2 rounds. Their latest funding was raised on Feb 7, 2018 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 7, 2018 Grant $11M 1 National Institutes of Health Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Sangamo Therapeutics is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant